GO:0032682 negative regulation of chemokine production: Immune Suppression Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032682 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of chemokine production, including chemokine biosynthesis and secretion.
• Negative regulation of chemokine production is essential for resolving inflammation and preventing chronic inflammatory and autoimmune diseases.
• Key negative regulators include MCPIP1 (ZC3H12A), CISH, type I interferons, and MAPK-dependent feedback mechanisms.
• Dysregulation of this process contributes to inflammatory bowel disease, granulomatous inflammation, and tumor immune evasion.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of negative regulators in chemokine production.
• Studying GO:0032682 requires integrated methods such as RNA-seq, cytokine arrays, phosphoproteomics, and reporter assays.
Description
Chemokines are small secreted proteins that direct leukocyte trafficking and are central to both protective immunity and pathological inflammation. The Gene Ontology term GO:0032682, negative regulation of chemokine production, captures the diverse cellular processes that suppress the synthesis or release of chemokines, thereby limiting excessive immune cell recruitment. This term is a biological process and encompasses negative regulation of chemokine biosynthetic process and negative regulation of chemokine secretion, reflecting the multiple layers at which chemokine output can be controlled. Understanding this process is critical because failure to restrain chemokine production underlies chronic inflammatory diseases, autoimmunity, and tumor immune evasion. Conversely, excessive suppression can impair host defense and vaccine responses. Researchers studying GO:0032682 aim to identify the molecular brakes on chemokine production, determine how they are engaged by physiological and pharmacological signals, and exploit them therapeutically. This article synthesizes authoritative QuickGO annotation data with real PubMed literature to provide a research-grade overview of the mechanisms, genes, disease links, and experimental models relevant to negative regulation of chemokine production.
negative regulation of chemokine production At A Glance
| GO ID | GO:0032682 |
|---|---|
| GO term | negative regulation of chemokine production |
| Ontology | biological_process |
| Synonym | down regulation of chemokine production; down-regulation of chemokine production; downregulation of chemokine production; inhibition of chemokine production; negative regulation of chemokine biosynthetic process; negative regulation of chemokine secretion |
| Major function | Suppresses the synthesis and/or secretion of chemokines to limit leukocyte recruitment and resolve inflammation |
| Related processes | Negative regulation of cytokine production; regulation of inflammatory response; negative regulation of immune effector process |
| Cellular locations | Cytoplasm, nucleus, endoplasmic reticulum, Golgi apparatus, extracellular space |
| Key negative regulators | MCPIP1 (ZC3H12A), CISH, type I interferons, MAPK phosphatases, ATF3 |
| Disease relevance | Inflammatory bowel disease, granulomatous inflammation, cancer immune evasion, neuroinflammation |
What Is GO:0032682?
GO:0032682, negative regulation of chemokine production, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of chemokine production. It includes negative regulation of chemokine biosynthetic process and negative regulation of chemokine secretion, and is synonymous with down regulation, down-regulation, downregulation, and inhibition of chemokine production. This term applies to all chemokines and to any cell type capable of producing them, including macrophages, dendritic cells, fibroblasts, and microglia.
Why Is negative regulation of chemokine production Important in Cell Biology?
Negative regulation of chemokine production is a fundamental homeostatic mechanism that prevents runaway inflammation and tissue damage. Without it, even transient microbial stimuli would lead to sustained chemokine gradients, uncontrolled leukocyte infiltration, and chronic inflammatory pathology. This process also shapes the tumor microenvironment, where suppression of chemokines such as CXCL9 and CXCL10 limits CD8 T cell recruitment and promotes immune evasion. In the central nervous system, type I interferon-mediated suppression of CXCL13 in microglia helps restrict neuroinflammation. Consequently, understanding GO:0032682 is essential for developing therapies that either enhance or release the brakes on chemokine production in inflammatory diseases, autoimmunity, and cancer.
• Prevents excessive leukocyte recruitment and tissue damage during infection and sterile inflammation.
• Promotes resolution of inflammation by terminating chemokine gradients.
• Limits immunopathology in chronic inflammatory diseases such as inflammatory bowel disease.
• Regulates granulomatous inflammation and macrophage-driven pathology.
• Controls anti-tumor immunity by modulating CXCL9/10 production and CD8 T cell infiltration.
• Restrains neuroinflammation via type I interferon-mediated suppression of microglial CXCL13.
• Modulates allergic airway inflammation by suppressing IL-13-induced CCL26 in lung fibroblasts.
• Provides targets for anti-inflammatory drug development and biomarker discovery.
• Influences vaccine responses and trained immunity by shaping chemokine kinetics.
• Is essential for maintaining immune homeostasis in mucosal tissues.
What Happens During negative regulation of chemokine production?
Initiation of negative feedback signals
In simple terms: The cell receives a stop signal that tells it to reduce chemokine output.
Negative regulation of chemokine production is initiated when cells encounter anti-inflammatory cytokines, type I interferons, or sustained Toll-like receptor (TLR) stimulation that triggers feedback inhibition. For example, type I interferons suppress microglial production of the lymphoid chemokine CXCL13, demonstrating that interferon signaling can directly initiate negative regulation. Similarly, repeated lipopolysaccharide (LPS) stimulation induces tolerance, a state in which chemokine production is markedly reduced upon re-stimulation. These initiating signals activate intracellular negative regulators such as MCPIP1 (ZC3H12A) and CISH, which then act on chemokine mRNA or signaling intermediates.
Transcriptional and post-transcriptional suppression
In simple terms: The cell stops making the mRNA instructions for chemokines or destroys them quickly.
Once negative feedback is engaged, chemokine gene transcription can be suppressed through inhibition of NF-kB and MAPK pathways, or through induction of transcriptional repressors such as ATF3. MCPIP1 functions as an RNase that degrades chemokine mRNAs, thereby reducing the pool of transcripts available for translation. In dendritic cells, mitogen-activated protein kinases (MAPKs) regulate TLR-induced chemokine production, and their negative regulation limits chemokine output. CISH, a cytokine-inducible SH2-containing protein, negatively regulates IL-13-induced CCL26 production in lung fibroblasts, likely by attenuating STAT6 signaling.
Inhibition of chemokine secretion
In simple terms: Even if some chemokine protein is made, the cell can block its release.
Negative regulation of chemokine production also includes inhibition of chemokine secretion, as reflected in the synonym negative regulation of chemokine secretion. This can occur through retention of chemokines in the endoplasmic reticulum or Golgi, enhanced intracellular degradation, or reduced trafficking of secretory vesicles. Macrophage transactivation for chemokine production has been identified as a negative regulator of granulomatous inflammation using agent-based modeling, suggesting that spatial and temporal control of secretion is critical. The exact molecular machinery for secretion inhibition varies by cell type and chemokine but often involves post-translational modifications and vesicle trafficking regulators.
Resolution of inflammation
In simple terms: The reduced chemokine levels allow inflammation to wind down.
The ultimate outcome of negative regulation of chemokine production is the resolution of inflammation. By lowering chemokine gradients, this process reduces the recruitment of neutrophils, monocytes, and lymphocytes to inflamed tissues. In the intestine, MCPIP1 restrains mucosal inflammation by orchestrating monocyte-to-macrophage maturation via an ATF3-AP1S2 axis, illustrating how negative regulation of chemokine production is coupled to tissue repair. In tumors, targeting macrophage-derived SPP1 enhances CD8 T cell infiltration via ROS-DNA fragment/cGAS-STING/STAT1-mediated CXCL9/10, showing that releasing the brakes on chemokine production can boost anti-tumor immunity.
Key Genes Involved in GO:0032682 negative regulation of chemokine production
The following genes and proteins are experimentally validated participants in negative regulation of chemokine production (GO:0032682) according to the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ZC3H12A (MCPIP1) | RNase that degrades chemokine mRNAs; restrains mucosal inflammation | Knockout mice develop severe inflammation; target for IBD therapy |
| CISH | Negative regulator of IL-13-induced CCL26 production in lung fibroblasts | Potential target for allergic airway diseases |
| ATF3 | Transcription factor mediating MCPIP1 effects on monocyte-macrophage maturation | Links negative regulation of chemokine production to tissue repair |
| AP1S2 | Adaptor protein in the ATF3-AP1S2 axis downstream of MCPIP1 | Modulates monocyte maturation and chemokine output |
| SPP1 (osteopontin) | Macrophage-derived factor that suppresses CXCL9/10 via ROS-DNA fragment/cGAS-STING/STAT1 | Targeting SPP1 enhances CD8 T cell infiltration in tumors |
| STAT1 | Transcription factor mediating CXCL9/10 induction; modulated by SPP1 | Central node in tumor immune evasion |
| cGAS-STING | Cytosolic DNA sensing pathway upstream of STAT1 and CXCL9/10 | Innate immune regulator of chemokine production |
| Type I interferons (IFN-alpha/beta) | Suppress microglial production of CXCL13 | Therapeutic potential in neuroinflammation |
| MAPK family (ERK, p38, JNK) | Regulate TLR-induced chemokine production in dendritic cells | Targets for anti-inflammatory drugs |
| TLR4 | Initiates signaling that can lead to tolerance and reduced chemokine production | Model for LPS tolerance and priming |
| NF-kB | Transcription factor driving chemokine genes; inhibited during negative regulation | Key node for anti-inflammatory intervention |
| IL-13 | Cytokine that induces CCL26; negatively regulated by CISH | Allergic inflammation model |
| CCL26 (eotaxin-3) | Chemokine suppressed by CISH in lung fibroblasts | Biomarker for eosinophilic asthma |
| CXCL13 | Lymphoid chemokine suppressed by type I interferons in microglia | Neuroinflammation target |
| CXCL9/CXCL10 | T cell-recruiting chemokines suppressed by SPP1 in tumors | Predictive biomarkers for immunotherapy |
| MCP-1 (CCL2) | Monocyte chemoattractant subject to negative regulation | Inflammatory disease model |
| IL-10 | Anti-inflammatory cytokine that can suppress chemokine production | Therapeutic cytokine |
| TGF-beta | Anti-inflammatory cytokine with chemokine-suppressive effects | Fibrosis and cancer model |
How Is negative regulation of chemokine production Regulated?
Negative regulation of chemokine production is itself tightly regulated at multiple levels. Type I interferons can suppress microglial CXCL13 production, indicating that interferon signaling is a physiological brake. Toll-like receptor-induced chemokine production in dendritic cells is controlled by MAPK pathways, and sustained MAPK activation can lead to feedback inhibition. LPS tolerance and priming differentially regulate cytokine and chemokine production, showing that prior exposure history shapes the magnitude of negative regulation. MCPIP1 (ZC3H12A) acts as an RNase to degrade chemokine mRNAs, and its expression is induced by inflammatory stimuli as a negative feedback loop. CISH is induced by IL-13 and negatively regulates CCL26 production in lung fibroblasts, linking cytokine signaling to chemokine suppression. In tumors, the SPP1-ROS-DNA fragment-cGAS-STING-STAT1 axis controls CXCL9/10 production, and targeting SPP1 releases this suppression. These examples illustrate that negative regulation of chemokine production is not a single pathway but a network of transcriptional, post-transcriptional, and signaling mechanisms.
negative regulation of chemokine production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ZC3H12A (MCPIP1) | Inflammatory bowel disease | Intestinal epithelial cell-specific knockout mice |
| SPP1 | Cancer immune evasion | Macrophage-specific SPP1 knockout in tumor models |
| CISH | Allergic airway inflammation | Lung fibroblast-specific CISH knockout or overexpression |
| Type I interferon receptor | Neuroinflammation | Microglia-specific IFNAR knockout mice |
| MAPK components | TLR-induced inflammation | Dendritic cell-specific MAPK knockout |
Inflammatory Bowel Disease
MCPIP1 (ZC3H12A) restrains mucosal inflammation by orchestrating intestinal monocyte-to-macrophage maturation via an ATF3-AP1S2 axis, and loss of this negative regulation leads to excessive chemokine production and colitis. This positions GO:0032682 as a central node in IBD pathogenesis and a target for therapeutic intervention.
Granulomatous Inflammation
Macrophage transactivation for chemokine production has been identified as a negative regulator of granulomatous inflammation using agent-based modeling, suggesting that dysregulation of this process contributes to granuloma formation and persistence. The balance between chemokine production and its negative regulation determines whether inflammation resolves or becomes chronic.
Cancer Immune Evasion
Targeting macrophage-derived SPP1 enhances CD8 T cell infiltration via ROS-DNA fragment/cGAS-STING/STAT1-mediated CXCL9/10 in the tumor microenvironment, demonstrating that negative regulation of chemokine production can suppress anti-tumor immunity. Releasing this brake is a promising strategy to improve immunotherapy responses.
Neuroinflammation
Type I interferons suppress microglial production of the lymphoid chemokine CXCL13, and failure of this negative regulation may contribute to neuroinflammatory diseases. Understanding GO:0032682 in microglia could inform therapies for multiple sclerosis and other CNS inflammatory conditions.
From negative regulation of chemokine production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ZC3H12A increase chemokine production? | ZC3H12A knockout cell line or mouse |
| Does CISH negatively regulate CCL26 in lung fibroblasts? | CISH overexpression and knockout in primary lung fibroblasts |
| Does SPP1 suppress CXCL9/10 in tumor macrophages? | SPP1 knockout macrophages co-cultured with CD8 T cells |
| Do type I interferons suppress microglial CXCL13? | IFNAR knockout microglia treated with IFN-beta |
| Does LPS tolerance reduce chemokine production? | Repeated LPS stimulation of macrophages or dendritic cells |
| Which MAPKs regulate TLR-induced chemokine production? | MAPK inhibitor or knockout dendritic cells |
How to Study the negative regulation of chemokine production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript changes including chemokine mRNAs | Identifying negative regulators of chemokine production |
| qPCR | Specific chemokine mRNA levels | Validating knockdown or knockout effects |
| ELISA / multiplex | Secreted chemokine protein concentrations | Quantifying production and secretion |
| Western blot | Phosphorylation of signaling intermediates | MAPK and STAT pathway analysis |
| Luciferase reporter | Chemokine promoter activity | Testing transcriptional suppression |
| Immunofluorescence | Cellular localization of chemokines and regulators | Secretion and trafficking studies |
| Phosphoproteomics | Global phosphorylation changes | Mapping negative feedback networks |
| Agent-based modeling | Emergent behavior of cell populations | Granuloma and tissue-level chemokine dynamics |
Transcriptomic Profiling
RNA-seq and quantitative PCR are used to measure chemokine mRNA levels following genetic or pharmacological manipulation of negative regulators. For example, MCPIP1 RNase activity can be assessed by measuring chemokine mRNA stability. CISH effects on IL-13-induced CCL26 are quantified by qPCR and ELISA.
Cytokine and Chemokine Arrays
Multiplex immunoassays and ELISA are used to quantify secreted chemokines in culture supernatants and serum. This is essential for distinguishing effects on production versus secretion. LPS tolerance studies rely on measuring multiple chemokines simultaneously.
Signaling Pathway Analysis
Phosphoproteomics and Western blotting for phosphorylated MAPKs, STATs, and NF-kB are used to dissect the signaling cascades that mediate negative regulation. Type I interferon suppression of CXCL13 involves JAK-STAT signaling.
Reporter Assays and Imaging
Luciferase reporters driven by chemokine promoters are used to measure transcriptional activity. Fluorescence microscopy and live-cell imaging can track chemokine secretion and vesicle trafficking. Agent-based modeling has been applied to understand macrophage transactivation in granulomas.
How CRISPR Can Be Used to Study GO:0032682 negative regulation of chemokine production
Knockout
CRISPR knockout of negative regulators such as ZC3H12A, CISH, or SPP1 is used to test whether loss of function increases chemokine production. For example, ZC3H12A knockout cells show elevated chemokine mRNAs and exacerbated inflammation. CISH knockout in lung fibroblasts enhances IL-13-induced CCL26.
Point Mutation
Point mutations can dissect catalytic domains or phosphorylation sites. For instance, mutating the RNase domain of MCPIP1 would test its role in chemokine mRNA degradation. Similarly, mutating STAT1 phosphorylation sites can reveal their importance in CXCL9/10 suppression.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of negative regulator expression and localization. A fluorescent reporter knocked into the CISH locus could monitor its induction by IL-13 in real time. Tagged MCPIP1 knock-in enables immunoprecipitation of associated RNAs.
Overexpression
CRISPR activation or lentiviral overexpression of negative regulators such as CISH or MCPIP1 can suppress chemokine production and reduce inflammation. Overexpression of CISH in lung fibroblasts blunts CCL26 production. Overexpression of MCPIP1 reduces chemokine levels and mucosal inflammation.
How EDITGENE Supports negative regulation of chemokine production Research
Researchers studying negative regulation of chemokine production-related genes often need to determine whether a candidate gene is causally involved in suppressing chemokine output, and to dissect the precise molecular steps affected. This requires robust, reproducible cell models with defined genetic alterations, which EDITGENE provides through CRISPR-based knockout, point mutation, knock-in, and overexpression services.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of chemokine production research.
Frequently Asked Questions About negative regulation of chemokine production
What is negative regulation of chemokine production (GO:0032682)?
GO:0032682 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of chemokine production, including chemokine biosynthesis and secretion.
What genes are involved in negative regulation of chemokine production?
Key genes include ZC3H12A (MCPIP1), CISH, ATF3, AP1S2, SPP1, STAT1, and type I interferon pathway components, as shown in studies of inflammation and cancer.
How does MCPIP1 regulate chemokine production?
MCPIP1 (ZC3H12A) acts as an RNase that degrades chemokine mRNAs and restrains mucosal inflammation via an ATF3-AP1S2 axis.
What is the role of CISH in chemokine regulation?
CISH is a negative regulator of IL-13-induced CCL26 production in lung fibroblasts, acting as a feedback inhibitor of cytokine signaling.
Do type I interferons suppress chemokine production?
Yes, type I interferons suppress microglial production of the lymphoid chemokine CXCL13, demonstrating a negative regulatory role in the CNS.
How is negative regulation of chemokine production studied experimentally?
Common methods include RNA-seq, qPCR, ELISA, Western blotting for signaling intermediates, reporter assays, and CRISPR knockout or overexpression models.
What diseases are linked to defective negative regulation of chemokine production?
Inflammatory bowel disease, granulomatous inflammation, cancer immune evasion, and neuroinflammation are associated with impaired negative regulation of chemokine production.
Can CRISPR be used to study negative regulation of chemokine production?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are widely used to dissect the function of negative regulators such as ZC3H12A, CISH, and SPP1.
What is the difference between negative regulation of chemokine production and secretion?
The GO term GO:0032682 includes both negative regulation of chemokine biosynthetic process and negative regulation of chemokine secretion, covering synthesis and release.
Which signaling pathways mediate negative regulation of chemokine production?
MAPK pathways, JAK-STAT signaling, and NF-kB feedback loops are involved, with type I interferons and anti-inflammatory cytokines acting as upstream triggers.
Conclusion
GO:0032682, negative regulation of chemokine production, is a critical biological process that restrains inflammation and shapes immune responses in health and disease. Key negative regulators such as MCPIP1, CISH, and type I interferons act at transcriptional, post-transcriptional, and secretory levels to limit chemokine output. Dysregulation of this process contributes to inflammatory bowel disease, granulomatous inflammation, cancer immune evasion, and neuroinflammation. Advances in CRISPR-based models and multi-omics profiling are accelerating the discovery of new components and therapeutic targets within this pathway. EDITGENE provides comprehensive services to support mechanistic and translational research on negative regulation of chemokine production.
References
- 1. Lu H et al.. 2023. MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.. Gut 72(5):882-895 PMID: 37015751
- 2. Wang J et al.. 2026. Targeting macrophage-derived SPP1 enhances CD8 T cell infiltration via ROS-DNA fragment/cGAS-STING/STAT1-mediated CXCL9/10 in tumor microenvironment.. J Immunother Cancer 14(1) PMID: 41571298
- 4. Mitchell D et al.. 2010. Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases.. Mol Immunol 47(11-12):2065-73 PMID: 20451253
- 5. Peck OM et al.. 2004. Differential regulation of cytokine and chemokine production in lipopolysaccharide-induced tolerance and priming.. Cytokine 26(5):202-8 PMID: 15157897
- 6. Takeshima H et al.. 2019. CISH is a negative regulator of IL-13-induced CCL26 production in lung fibroblasts.. Allergol Int 68(1):101-109 PMID: 30197185
- 7. Moyo D et al.. 2018. Macrophage Transactivation for Chemokine Production Identified as a Negative Regulator of Granulomatous Inflammation Using Agent-Based Modeling.. Front Immunol 9:637 PMID: 29636754
- 8. Esen N et al.. 2014. Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13.. Glia 62(9):1452-62 PMID: 24829092
